ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Oral BPC-157 For Potential Gut Health
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="BadassBlues" data-source="post: 271684" data-attributes="member: 38526"><p>[URL unfurl="true"]https://pubmed.ncbi.nlm.nih.gov/28839430/[/URL]</p><p></p><h3>Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME</h3><p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Drmic+D&cauthor_id=28839430" target="_blank">Domagoj Drmic</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kolenc+D&cauthor_id=28839430" target="_blank">Danijela Kolenc</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ilic+S&cauthor_id=28839430" target="_blank">Spomenko Ilic</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Bauk+L&cauthor_id=28839430" target="_blank">Lara Bauk</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sever+M&cauthor_id=28839430" target="_blank">Marko Sever</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zenko+Sever+A&cauthor_id=28839430" target="_blank">Anita Zenko Sever</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Luetic+K&cauthor_id=28839430" target="_blank">Kresimir Luetic</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Suran+J&cauthor_id=28839430" target="_blank">Jelena Suran</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Seiwerth+S&cauthor_id=28839430" target="_blank">Sven Seiwerth</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sikiric+P&cauthor_id=28839430" target="_blank">Predrag Sikiric</a> <a href="https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1" target="_blank">1</a></p><p>Affiliations expand</p><ul> <li data-xf-list-type="ul">PMID: <strong>28839430</strong></li> <li data-xf-list-type="ul">PMCID: <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5550779/" target="_blank">PMC5550779</a></li> <li data-xf-list-type="ul">DOI: <a href="https://doi.org/10.3748/wjg.v23.i29.5304" target="_blank">10.3748/wjg.v23.i29.5304</a></li> </ul><p>Free PMC article</p><h3>Abstract</h3><p><strong>Aim: </strong>To counteract/reveal celecoxib-induced toxicity and NO system involvement.</p><p><strong>Methods: </strong>Celecoxib (1 g/kg b.w. ip) was combined with therapy with stable gastric pentadecapeptide BPC 157 (known to inhibit these lesions, 10 μg/kg, 10 ng/kg, or 1 ng/kg ip) and L-arginine (100 mg/kg ip), as well as NOS blockade [N(G)-nitro-L-arginine methyl ester (L-NAME)] (5 mg/kg ip) given alone and/or combined immediately after celecoxib. Gastrointestinal, liver, and brain lesions and liver enzyme serum values in rats were assessed at 24 h and 48 h thereafter.</p><p><strong>Results: </strong>This high-dose celecoxib administration, as a result of NO system dysfunction, led to gastric, liver, and brain lesions and increased liver enzyme serum values. The L-NAME-induced aggravation of the lesions was notable for gastric lesions, while in liver and brain lesions the beneficial effect of L-arginine was blunted. L-arginine counteracted gastric, liver and brain lesions. These findings support the NO system mechanism(s), both NO system agonization (L-arginine) and NO system antagonization (L-NAME), that on the whole are behind all of these COX phenomena. An even more complete antagonization was identified with BPC 157 (at both 24 h and 48 h). A beneficial effect was evident on all the increasingly negative effects of celecoxib and L-NAME application and in all the BPC 157 groups (L-arginine + BPC 157; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157). Thus, these findings demonstrated that BPC 157 may equally counteract both COX-2 inhibition (counteracting the noxious effects of celecoxib on all lesions) and additional NOS blockade (equally counteracting the noxious effects of celecoxib + L-NAME).</p><p><strong>Conclusion: </strong>BPC 157 and L-arginine alleviate gastrointestinal, liver and brain lesions, redressing NSAIDs' post-surgery application and NO system involvement.</p><p><strong>Keywords: </strong>BPC 157; Celecoxib; L-arginine; N(G)-nitro-L-arginine methyl ester; Rats.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/disclaimer/" target="_blank">PubMed Disclaimer</a></p><p></p><h3></h3></blockquote><p></p>
[QUOTE="BadassBlues, post: 271684, member: 38526"] [URL unfurl="true"]https://pubmed.ncbi.nlm.nih.gov/28839430/[/URL] [HEADING=2]Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME[/HEADING] [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Drmic+D&cauthor_id=28839430']Domagoj Drmic[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Kolenc+D&cauthor_id=28839430']Danijela Kolenc[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Ilic+S&cauthor_id=28839430']Spomenko Ilic[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Bauk+L&cauthor_id=28839430']Lara Bauk[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Sever+M&cauthor_id=28839430']Marko Sever[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Zenko+Sever+A&cauthor_id=28839430']Anita Zenko Sever[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Luetic+K&cauthor_id=28839430']Kresimir Luetic[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Suran+J&cauthor_id=28839430']Jelena Suran[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Seiwerth+S&cauthor_id=28839430']Sven Seiwerth[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL], [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Sikiric+P&cauthor_id=28839430']Predrag Sikiric[/URL] [URL='https://pubmed.ncbi.nlm.nih.gov/28839430/#full-view-affiliation-1']1[/URL] Affiliations expand [LIST] [*]PMID: [B]28839430[/B] [*]PMCID: [URL='http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5550779/']PMC5550779[/URL] [*]DOI: [URL='https://doi.org/10.3748/wjg.v23.i29.5304']10.3748/wjg.v23.i29.5304[/URL] [/LIST] Free PMC article [HEADING=2]Abstract[/HEADING] [B]Aim: [/B]To counteract/reveal celecoxib-induced toxicity and NO system involvement. [B]Methods: [/B]Celecoxib (1 g/kg b.w. ip) was combined with therapy with stable gastric pentadecapeptide BPC 157 (known to inhibit these lesions, 10 μg/kg, 10 ng/kg, or 1 ng/kg ip) and L-arginine (100 mg/kg ip), as well as NOS blockade [N(G)-nitro-L-arginine methyl ester (L-NAME)] (5 mg/kg ip) given alone and/or combined immediately after celecoxib. Gastrointestinal, liver, and brain lesions and liver enzyme serum values in rats were assessed at 24 h and 48 h thereafter. [B]Results: [/B]This high-dose celecoxib administration, as a result of NO system dysfunction, led to gastric, liver, and brain lesions and increased liver enzyme serum values. The L-NAME-induced aggravation of the lesions was notable for gastric lesions, while in liver and brain lesions the beneficial effect of L-arginine was blunted. L-arginine counteracted gastric, liver and brain lesions. These findings support the NO system mechanism(s), both NO system agonization (L-arginine) and NO system antagonization (L-NAME), that on the whole are behind all of these COX phenomena. An even more complete antagonization was identified with BPC 157 (at both 24 h and 48 h). A beneficial effect was evident on all the increasingly negative effects of celecoxib and L-NAME application and in all the BPC 157 groups (L-arginine + BPC 157; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157). Thus, these findings demonstrated that BPC 157 may equally counteract both COX-2 inhibition (counteracting the noxious effects of celecoxib on all lesions) and additional NOS blockade (equally counteracting the noxious effects of celecoxib + L-NAME). [B]Conclusion: [/B]BPC 157 and L-arginine alleviate gastrointestinal, liver and brain lesions, redressing NSAIDs' post-surgery application and NO system involvement. [B]Keywords: [/B]BPC 157; Celecoxib; L-arginine; N(G)-nitro-L-arginine methyl ester; Rats. [URL='https://pubmed.ncbi.nlm.nih.gov/disclaimer/']PubMed Disclaimer[/URL] [HEADING=2][/HEADING] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Oral BPC-157 For Potential Gut Health
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top